Science, a brain-computer interface startup, closed a $400 million Series D round, topping a week where 10 U.S. startups raised over $100 million each. Across the Atlantic, AI biotech company Isomorphic Labs secured a staggering $5 billion.
TL;DR
- Science's $400M round highlights a strong week for deep tech funding, with AI and biotech leading the charge.
- Isomorphic Labs' $5B raise is the largest of the week and underscores the growing intersection of AI and biotech.
- The week's funding rounds suggest continued investor confidence in transformative technologies, despite recent tech stock volatility.
What happened
Science, a neurotech startup based in Alameda, California, secured $400 million in Series D funding, bringing its total funding to over $900 million. The round was led by an undisclosed investor. This follows a week where tech stocks experienced significant volatility, although the private market showed resilience with several large funding rounds.
Isomorphic Labs, a UK-based AI biotech startup, raised $5 billion in Series C funding, led by Greenoaks and Sequoia Capital. The company applies AI to drug discovery and has offices in Massachusetts and Switzerland. This raise is the largest of the week and one of the largest in biotech history.
Other notable rounds include Model ML's $250 million Series B for its AI fintech platform, and Noeri's $110 million launch round for enterprise AI. Galvanize Therapeutics, Ramon.Space, Marrow Therapeutics, Seawolf Therapeutics, BrightAI, and Vincue also closed rounds over $100 million.
Why it matters
This week's funding rounds demonstrate strong investor interest in deep tech, particularly in AI, biotech, and neurotech. Science's raise highlights the growing potential of brain-computer interfaces, while Isomorphic Labs' massive round underscores the power of AI in drug discovery. For developers and startups, this signals continued opportunities for innovation and investment in these areas.
The competitive landscape is heating up, with significant capital flowing into transformative technologies. Investors are betting big on companies that can deliver breakthroughs in healthcare, finance, and other critical sectors. This could spur further advancements and accelerate the development of new products and services.
However, the recent volatility in tech stocks raises questions about the sustainability of these valuations. While private markets have shown resilience so far, persistent downward pressure could eventually impact startup funding. Founders and investors should monitor market trends closely.
Key facts
- Science raised $400 million in Series D funding, bringing its total funding to over $900 million.
- Isomorphic Labs secured $5 billion in Series C funding, the largest raise of the week.
- Model ML closed a $250 million Series B round at a $1.5 billion valuation.
- Noeri launched with $110 million in initial funding for its enterprise AI platform.
- Galvanize Therapeutics raised $130 million in Series D funding for its biotech platform.
- Ramon.Space secured $124 million in Series B funding for space computing infrastructure.
- Marrow Therapeutics announced its launch with a combined $173 million in Series A and B funding.
- Seawolf Therapeutics raised $100 million in funding for its novel DNA delivery platform.
Context
The AI and biotech sectors have seen significant growth in recent years, driven by advancements in machine learning, data analysis, and genetic engineering. The intersection of these fields is creating new opportunities for innovation and investment. For example, AI is being used to accelerate drug discovery, while brain-computer interfaces promise to revolutionize how we interact with technology.
Despite the recent volatility in tech stocks, private markets have shown resilience. Investors continue to bet on transformative technologies, even as public markets experience turbulence. This suggests that the long-term potential of these technologies remains compelling, even in the face of short-term market fluctuations.
For developers and startups, this week's funding rounds highlight the importance of focusing on cutting-edge technologies. Companies that can deliver breakthroughs in AI, biotech, and neurotech are likely to attract significant investment and drive the next wave of innovation.
